Policymakers now prioritize growth over inflation control. Read why I'm betting on cyclical growth, positioning my portfolio ...

Columbia Threadneedle’s Corporate Income Fund returned 2.05% in Q2 2025 amid market volatility and tariff shocks. Explore how ...

The most likely range for 3-month bill yields falls to the 1% to 2% range within 30 months, according to this week’s ...

Columbia Threadneedle’s Convertible Securities Fund beat its benchmark in Q2 2025, fueled by tech and crypto-linked ...

XONE offers low-cost, short-duration Treasury exposure, making it attractive for those seeking limited duration risk. See why ...

Suzano maintains a strong cost advantage in pulp production, exporting to stable and growing markets, creating a solid moat ...

Columbia Threadneedle’s Contrarian Core Fund beat its benchmark in Q2 2025 amid AI-fueled tech gains. Explore what drove ...

Gilead Sciences' valuation exceeds fundamentals, prompting a SELL recommendation. Discover why this $150B biopharma stock may ...

Columbia Threadneedle’s Bond Fund beat its benchmark in Q2 2025 with smart duration and credit picks. See how it navigated ...

Google ( NASDAQ: GOOG) agreed on Monday to pay a fine of A$55 million ($35.8 million) in Australia after the country’s ...

After a strong June, the REIT sector recovery stalled in July as REITs fell to a -6.42% year-to-date return. Read more here.

Definitive Health beats on Q2 revenue and EPS, but weak Life Sciences subscriptions and structural pressures remain. Read why ...